Regulatory Update

ANVISA's Collegiate Board Meeting Opens to Public Participation

ANVISA's DICOL Discusses Essential Medical Device Regulations, Enhancing Safety and Regulatory Convergence in Brazil.

Published on:
March 1, 2024

On March 6, 2024, ANVISA held DICOL, which are meetings of the Collegiate Board (Dicol) of the National Health Surveillance Agency (Anvisa) that occur periodically and are open to society's participation.

At the DICOL meetings, there are several deliberative matters regarding ANVISA's 2024-2025 regulatory agenda, as well as decisions on some regulatory processes.

In this last meeting (03/06/2024), important regulatory topics focused on the area of medical devices were discussed. They are:

1) Approval of the revision text of the essential safety and performance requirements for medical devices and medical devices for in vitro diagnostics, in yet another regulation aligned with a document issued by IMDRF, maintaining our commitment to regulatory convergence.

Pure Global’s Regulatory Expert:  Super relevant - Reliance topic in which ANVISA has been committed and, which will bring more and more business to Brazil. (RDC 741:2022)

2) Approval of the Proposal to Open an Administrative Regulation Process to restrict the use of dental amalgam in pregnant women, breastfeeding women, and in primary dentition in individuals up to 15 years of age in health services, in line with what is established in the Minamata Convention.

Pure Global’s Regulatory Expert: ANVISA is always concerned with patient safety.

3) Approval of the Proposals for the Single Opening of the Administrative Regulation Process and Normative Instruction to update the list of Technical Standards for the certification of equipment under the health surveillance regime, within the scope of the Brazilian Conformity Assessment System (SBAC).

Pure Global’s Regulatory Expert: De-bureaucratization of the regulatory process in Brazil.

4) Approval of the proposal for extraordinary, emergency, and temporary prioritization of the analysis of petitions for registration of medical devices for in vitro diagnosis for Dengue, which is an important contribution from Anvisa in the joint strategy with the MS to expand the arsenal for diagnosis and combating Dengue Dengue.

Pure Global’s Regulatory Expert:  Excellent theme for attracting IVD medical devices to Brazil.

Source:  https://www.linkedin.com/posts/augusto-geyer-48623614b_2%C2%AA-reuni%C3%A3o-ordin%C3%A1ria-p%C3%BAblica-da-dicol-2024-activity-7171271090286051328-5vN2?utm_source=share&utm_medium=member_ios

Furthermore, the issues above are linked to ANVISA's regulatory agenda 2024-2025, below are the topics to be addressed in the regulatory agenda:

Subscribe to newsletter
Subscribe to receive the latest blog posts to your inbox every week.
By subscribing, you agree to our Terms and Conditions.
Thank you for subscribing!
Oops! Something went wrong while submitting the form.
Read more

Latest News

Browse our news hub featuring company announcements, regulatory updates, and industry insights to keep you informed and ahead of the curve.

In the dynamic world of MedTech compliance, AI plays a pivotal role. It streamlines regulatory research, enhances data analytics for compliance, and automates tasks, ensuring efficiency and accuracy. Looking ahead, AI-driven digital tools promise even greater efficiency, enabling global collaboration and driving the MedTech industry towards innovation and growth.

Regulatory Update
April 5, 2024

Stay updated with the latest EU regulations and guidance in the medical device industry. Check out our comprehensive summary of key updates including new standards, legislative acts, and guidance documents. Dive in now to stay compliant and informed!

Company Update
April 2, 2024

Phyllis Meng, CEO of Pure Global, shares insights into their innovative approach to revolutionizing the medical device industry.

Company Update
March 18, 2024

Pure Global introduces a new brand and website to boost global outreach and improve client service clarity.

Contact us
Request information

Let's Talk,
Anywhere You Are.

Whether looking for more information or ready to partner with us, we're here to guide you through every step of the regulatory process.

Our closest representative will get back to you within 24 hours.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest Blog Content

Explore our collection of articles, success stories, and regulatory updates, designed to help you take your product global.

Blog Article
New Standards in Medical Device Cybersecurity

Raising cybersecurity standards for medical devices necessitates manufacturers' compliance with new global regulations.

Blog Article
A Strategic Alliance with Pure Global in Brazil

Brazil stands as Latin America's largest medical device market, regulated by ANVISA with recent updates to accommodate new technologies and international harmonization.

Blog Article
US Regulatory Insights: Pure Global Collaboration 

Combining expert regulatory guidance with cutting-edge clinical laboratory support to streamline the FDA approval process.

Blog Article
Partnering with Pure Global Singapore

With a population of 5+ million, Singapore has the highest GDP per capita in Asia, according to Trading Economics.